Investors
We are committed to creating value for our society and our shareholders through life-changing peptide therapeutics for people who need them.
-
Share price information
ZEAL (COP)
915.00DKKZealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL. Access investor information including full share price in DKK plus investor tools.
More Stock information -
Annual report 2023
-
Corporate presentation
76%
of our operating expenditure focused on R&D in 2023
10
analysts covering Zealand Pharma
62.65m
shares outstanding as of March 31, 2024
300+
employees in Denmark and the United States
Catch up on our past events
View the webcasts and documents from our past events here
H1 2024 Interim Report
Latest financial report
On August 15, 2024, Zealand Pharma reported interim results for the quarter and half year ended June 30, 2024 and provided a company update.
Latest news
Newsroom-
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
READ MORE -
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
READ MORE -
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
READ MORE -
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
READ MORE
Stay up-to-date with the latest news from Zealand
Sign up to receive press releases and important company announcements directly to your inbox
Financial calendar
See all financial events-
Q3 Financial Results / Interim Report Third Quarter 2024
ADD TO CALENDAR
-
Corporate governance
At Zealand Pharma, our corporate governance structure aims to support long-term financial performance, meet the obligations of our stakeholders, and create value for shareholders and society.
-
Annual general meeting
The Annual General Meeting for 2024 was held on Wednesday, March 20th, 2024 at 15:00 CET. Find additional information and the webcast recording on the AGM page.
-
Analyst coverage
Zealand Pharma is currently covered by 10 analysts and financial institutions across the U.S and Europe.
Safety, tolerability, and clinical effects of ZP8396, an amylin analog
Featured publications
Results from a 6-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.
An innovative R&D pipeline
More investor information
Investor relations policy
We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.
Prospectus
Read our latest prospectus and prospectus summary from April 3, 2023.
Investor and Media contacts
